BACK

Kylor Hua

Kylor Hua

Vice President

New York Office  |  kylor.hua@torreya.com   |   212.257.5817

Kylor Hua, a Vice President at Torreya, advises clients on strategic transactions in the US and Asia.

He joined Torreya in 2013, having previously worked as a summer analyst at the firm.

Kylor received a B.A., magna cum laude from the University of Rochester. He holds double majors in economics and business strategy, and brain and cognitive science, and a minor in Japanese. He is fluent in Mandarin and Japanese.

Selected Transactions

Alphora Research
Sale of company to
Eurofins Scientific
Undisclosed
June 2017
Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
Mallinckrodt Pharmaceuticals
Sale of
Intrathecal business to
Piramal
$203 million
March 2017
VistaPharm
Company sale to
Warburg Pincus
$100+ million
December 2015
Concordia International Corp.
Acquisition of
Donnatal® from
Revive Pharmaceuticals
$328 million
May 2014
EA Pharma
License of AJT-240 in hemodialysis in China to
Tasly Pharmaceutical Group Co., Ltd.
Up to $24 million
June 2018
Somerset Therapeutics
and affiliate Wintac, Limited acquired by
Endo
$190 million
April 2018
Mission Pharmacal
Sale of consumer
products to
MainPointe Pharmaceuticals
Undisclosed
February 2018
Sandoz
Sale of
ANDA portfolio to
CASI Pharmaceuticals
Undisclosed
January 2018
Zylera
Sale to
Cerecor
Up to $34 million
November 2017
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
Apollo Endosurgery
Merger with
Lpath
$251 million
December 2016
Conatus Pharmaceuticals
Collaboration agreement for Emricasan with
Novartis
$50 million upfront
December 2016
Sandoz
Sale of ANDA
portfolio to
Upsher-Smith
Undisclosed
October 2016
Hikma Pharmaceuticals
Sale of abbreviated
new drug applications
Undisclosed
Undisclosed
February 2016
H2-Pharma
Sale of assets to
ANI Pharmaceuticals
$10 million
February 2016
telegent
Acquisition of
Alveda Pharmaceuticals
CAD $47 million
October 2015
XOMA
License of global rights
for Anti-TGF-beta
antibody program to
Novartis
Up to $517 million
October 2015
Teva
Sale of abbreviated
new drug application
portfolio to
ANI Pharmaceuticals
$25 million +
profit share
July 2015
Sandoz
Sale of
Zonalon® to
Renaissance Pharma
Undisclosed
March 2015
Sandoz
Divestiture of
certain abbreviated
new drug applications to
IDT Australia
Up to $18 million
October 2014